Literature DB >> 34169351

Long-term progression of geographic atrophy in age-related macular degeneration does the phakic status matter?

Carolina Madeira1, Gonçalo Godinho2, Rodrigo Vilares-Morgado2,3, João Beato2,4, João Pinheiro-Costa2,4, Ângela Carneiro2,4, Fernando Falcão-Reis2,4, Manuel Falcão2,4.   

Abstract

PURPOSE: To assess the long-term risk of geographic atrophy (GA) progression after cataract surgery.
METHODS: Subjects with GA secondary to AMD followed for at least 1 year with fundus autofluorescence imaging and with at least two visits at our centre were included. Patients with wet AMD, disciform scar, past history of intravitreal injections or laser treatment, other maculopathies and with poor quality images were excluded. GA area at baseline and at follow-up visit was measured. Three study groups were defined according to their phakic status: (A) pseudophakia, (B) phakic and (C) phacoemulsification surgery performed during the study. Differences of GA area progression were compared between these study groups. In addition, comparison between GA progression rate in group (C) before and after the surgery was performed. The enlargement rate (ER) was calculated for lesion size after transforming the measurements to the square-root scale.
RESULTS: A total of 92 eyes of 92 patients were enrolled. Median follow-up time was 4 [1-10] years. Regarding the eye's phakic status, 29 (31.5%) were pseudophakic and 63 (68.5%) were phakic; of these, 22 underwent phacoemulsification during the study. Overall, the median baseline and follow-up area of GA were 1.42 [0.04-32.10] mm2 and 6.48 [0.25-47.40] mm2, respectively. The ER was similar between phakic and pseudophakic eyes (0.18 [0.01-1.03] vs 0.15 [0.01-0.65] mm/year, p = 0.62). In patients that underwent cataract surgery during the study, the GA ER remained stable (0.13 [0.01-0.92] vs 0.14 [0.01-0.63] mm/year, p = 0.43).
CONCLUSION: These results suggest that cataract surgery does not increase the risk of pre-existing GA progression. Therefore, cataract surgery seems safe and a potential therapeutic weapon to improve visual acuity and consequently quality of life in GA patients.

Entities:  

Keywords:  Cataract surgery; Fundus autofluorescence; Geographic atrophy; Phacoemulsification; Phakic; Progression; Pseudophakic

Year:  2021        PMID: 34169351     DOI: 10.1007/s00417-021-05255-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  29 in total

Review 1.  Geographic atrophy: Etiopathogenesis and current therapies.

Authors:  M Sastre-Ibáñez; A Barreiro-González; R Gallego-Pinazo; R Dolz-Marco; B García-Armendariz
Journal:  Arch Soc Esp Oftalmol (Engl Ed)       Date:  2017-09-05

Review 2.  Recent approaches to evaluating and monitoring geographic atrophy.

Authors:  Voraporn Chaikitmongkol; Mongkol Tadarati; Neil M Bressler
Journal:  Curr Opin Ophthalmol       Date:  2016-05       Impact factor: 3.761

3.  Risk factors for age-related macular degeneration: findings from the Andhra Pradesh eye disease study in South India.

Authors:  Sannapaneni Krishnaiah; Taraprasad Das; Praveen K Nirmalan; Rishita Nutheti; Bindiganavale R Shamanna; Gullapalli N Rao; Ravi Thomas
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

4.  Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.

Authors:  Frank G Holz; Srinivas R Sadda; Brandon Busbee; Emily Y Chew; Paul Mitchell; Adnan Tufail; Christopher Brittain; Daniela Ferrara; Sarah Gray; Lee Honigberg; Jillian Martin; Barbara Tong; Jason S Ehrlich; Neil M Bressler
Journal:  JAMA Ophthalmol       Date:  2018-06-01       Impact factor: 7.389

5.  Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study.

Authors:  Marc Biarnés; Luis Arias; Jordi Alonso; Míriam Garcia; Míriam Hijano; Anabel Rodríguez; Anna Serrano; Josep Badal; Hussein Muhtaseb; Paula Verdaguer; Jordi Monés
Journal:  Am J Ophthalmol       Date:  2015-05-15       Impact factor: 5.258

Review 6.  The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Authors:  Monika Fleckenstein; Paul Mitchell; K Bailey Freund; SriniVas Sadda; Frank G Holz; Christopher Brittain; Erin C Henry; Daniela Ferrara
Journal:  Ophthalmology       Date:  2017-10-27       Impact factor: 12.079

7.  Is age-related maculopathy associated with cataracts?

Authors:  R Klein; B E Klein; Q Wang; S E Moss
Journal:  Arch Ophthalmol       Date:  1994-02

8.  Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.

Authors:  Johanna M Colijn; Gabriëlle H S Buitendijk; Elena Prokofyeva; Dalila Alves; Maria L Cachulo; Anthony P Khawaja; Audrey Cougnard-Gregoire; Bénédicte M J Merle; Christina Korb; Maja G Erke; Alain Bron; Eleftherios Anastasopoulos; Magda A Meester-Smoor; Tatiana Segato; Stefano Piermarocchi; Paulus T V M de Jong; Johannes R Vingerling; Fotis Topouzis; Catherine Creuzot-Garcher; Geir Bertelsen; Norbert Pfeiffer; Astrid E Fletcher; Paul J Foster; Rufino Silva; Jean-François Korobelnik; Cécile Delcourt; Caroline C W Klaver
Journal:  Ophthalmology       Date:  2017-07-14       Impact factor: 12.079

Review 9.  THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.

Authors:  David S Boyer; Ursula Schmidt-Erfurth; Menno van Lookeren Campagne; Erin C Henry; Christopher Brittain
Journal:  Retina       Date:  2017-05       Impact factor: 4.256

View more
  1 in total

1.  The intraocular implant and visual rehabilitation improve the quality of life of elderly patients with geographic atrophy secondary to age-related macular degeneration.

Authors:  Jana Nekolova; Jan Kremlacek; Jiri Lukavsky; Radovan Sikl; Martin Sin; Jana Langrova; Jana Szanyi; Nada Jiraskova
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-19       Impact factor: 3.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.